European Companies Search Engine
EU funding (€8,000,000): The Integrate study : An adaptive platform trial for the development of a new intervention to combat Lassa fever in Africa Hor1 Jul 2023 EU Research and Innovation programme "Horizon"
Text
The Integrate study : An adaptive platform trial for the development of a new intervention to combat Lassa fever in Africa
Lassa fever (LF) is an acute febrile illness associated with bleeding, organ failure, and shock caused by Lassa virus. LF causes outbreaks in West African with in-hospital mortality up to 12%. Challenges in the clinical care of patients are multiple due to the limited availability of LF molecular diagnostics, the risk for nosocomial transmission, and the limited treatment options.There are currently no safe and effective treatment options available for LF, except ribavirin, the efficacy of which is debated. The clinical development and accessibility of effective treatment options would be a game-changer towards reducing mortality associated with this disease and limiting its socio-economic impact. Nigeria is the country by far most affected by LF in the world with about 80% of global cases. The INTEGRATE consortium builds on a more than 15 years lasting highly successful collaboration between leading European and West African institutions focusing on the joint priority to better understand, manage, and combat LF in West Africa. The overall objective of the INTEGRATE project is to establish a GCP-compliant adaptive clinical platform trial in West Africa (Nigeria and other countries) to test the efficacy, tolerability and safety of repurposed and novel drug candidates for the treatment of LF. To address this objective, we focus our activities on 3 specific objectives: - to develop and implement an adaptive randomised controlled phase II-III clinical platform trial evaluating drugs with proven preclinical activity against LF. - to build capacity for sustainable and independently conducted clinical research in West Africa by developing site, laboratory and medical care capacity through North-South and South-South technology transfer and training. This activity encompasses capacity building of the lead Nigerian institution in GCP compliant clinical trial sponsorship. - to engage communities with the proposed work plan and to assess acceptability of the trial.
Funded Companies:
| Company name | Funding amount |
| Alex Ekwueme Federal University Teaching Hospital Abakaliki | ? |
| Association PAC-CI | €259,411 |
| Bernhard-Nocht-Institut Fuer Tropenmedizin | €1,939,750 |
| Centre de Recherches Medicales de Lambaréné | €111,500 |
| Federal Medical Centre OWO | €474,534 |
| Institut National de la Sante et de la Recherche Medicale | €200,000 |
| Irrua Specialist Teaching Hospital Board OF Management | €1,649,868 |
| THE Alliance for International Medical Action | €2,242,172 |
| Universite de Bordeaux | €979,015 |
| University OF Hamburg | €143,750 |
Source: https://cordis.europa.eu/project/id/101103204
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Alex Ekwueme Federal University Teaching Hospital Abakaliki, Abakaliki, Nigeria.